| Literature DB >> 28298909 |
Rosario Morales-Espinosa1, Gabriela Delgado1, Luis F Espinosa1, Dassaev Isselo2, José L Méndez1, Cristina Rodriguez3, Guadalupe Miranda4, Alejandro Cravioto5.
Abstract
Pseudomonas aeruginosa is an opportunistic pathogen and is associated with nosocomial infections. Its ability to thrive in a broad range of environments is due to a large and diverse genome of which its accessory genome is part. The objective of this study was to characterize P. aeruginosa strains isolated from children who developed bacteremia, using pulse-field gel electrophoresis, and in terms of its genomic islands, virulence genes, multilocus sequence type, and antimicrobial susceptibility. Our results showed that P. aeruginosa strains presented the seven virulence genes: toxA, lasB, lecA, algR, plcH, phzA1, and toxR, a type IV pilin alleles (TFP) group I or II. Additionally, we detected a novel pilin and accessory gene, expanding the number of TFP alleles to group VI. All strains presented the PAPI-2 Island and the majority were exoU+ and exoS+ genotype. Ten percent of the strains were multi-drug resistant phenotype, 18% extensively drug-resistant, 68% moderately resistant and only 3% were susceptible to all the antimicrobial tested. The most prevalent acquired β-Lactamase was KPC. We identified a group of ST309 strains, as a potential high risk clone. Our finding also showed that the strains isolated from patients with bacteremia have important virulence factors involved in colonization and dissemination as: a TFP group I or II; the presence of the exoU gene within the PAPI-2 island and the presence of the exoS gene.Entities:
Keywords: Pseudomonas aeruginosa; ST309; TFP alleles; bacteremia; children; exoS and exoU genes; genomics island
Year: 2017 PMID: 28298909 PMCID: PMC5331068 DOI: 10.3389/fmicb.2017.00313
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
Figure 1Restriction Patterns created with . DNA ladder of 100 bp (Invitrogen by Thermo Fisher Scientific, Inc.) and 50 bp (Thermo Fisher Scientific, Inc.) (lines 1 and 8, respectively). PCR products from P. aeruginosa PA14 strain, PAO1 strain and a 1208 clinical strain, the primers: forward 5′ ACTCGTGCGTCCCTTCGTG 3′ and reverse 5′ GATACTCTGCTGACCTCGCTCTC 3′ were used (lines 2, 4, and 6, respectively). Restriction pattern from PA14 strain product, which gave a restriction pattern of two bands for the exoT gene: one of 292 bp and the other of 233 bp (line 3). Restriction pattern from PAO1 strain product, which present both exoT and exoS genes, the bands size correspond to 86, 122, 140, 168, 29, and 233 bp (line 5). Restriction pattern from PCR product of one of our strains, this strain only present the exoS gene, which produced a pattern of four bands: 86, 122, 140, and 168 bp (line 7).
Figure 2Pulse-Field gel electrophoresis (PFGE) profile dendrogram and genetic and phenotypic characteristics of . The dendrogram was generated by Dice similarity coefficient (Dice, 1945) and UPGMA (Day and Edelsbrunner, 1984) clustering methods by using PFGE images of SpeI digested genomic DNA. The scale bar shows the correlation coefficient (%). Underlying disease (Dx): PNET, primary neuroectodermal tumor; BD-TEF, bronchopulmonary dysplasia-tracheoesophageal fistula; PDA, persistent ductus arteriosus; SGER, severe gastroesophageal reflux; ALL, acute lymphoblastic leukemia; VSD, ventricular septal defect; BD, bronchopulmonary dysplasia; CAP, community acquired pneumonia; NDI, nephrogenic diabetes insipidus; CKD, chronic kidney disease; TEF, tracheoesophageal fistula; AML, acute myeloid leukemia. Asterisk indicate a new ST, which has not been assigned. MDR, Multi-Drug Resistant; MR Moderately Resistant; XDR Extensively drug Resistant. The pili alleles were obtained according to Kus's characterization (Kus et al., 2004), in which P. aeruginosa type IV pili are divided into five distinct phylogenetic groups. The GEIs genotype was assigned base on the presence/absence of genomic island, 12 different GEIs genotypes were found (for details see Table S2, Supplementary Material). The resistance profile was formed by a number and a letter: the number indicates how many antibiotics the strain was resistant to; the letters were assigned alphabetically to differentiate among the antimicrobial combinations for which the strains were resistant (detailed information is shown in Table S3, Supplementary Material).
Genomic islands detection and susceptibility profile in .
| 1197 | Male/8 years | Acute lymphoblastic leukemia | TI, PI, TM, PT, CA, FE, IM, AZ, AM, GE, TO, PO, CI, LO, NO, LE | CB, CT, ME | CR | PAGI-1, PAPI-1, PAPI-2, pKLC102 [2] |
| 1210 | Female/1 year | Hemophagocytic syndrome | IM, ME, AM, GE, TO, PO, CI, LO, NO, LE | CB, TI, TM, CA, FE, AZ | PI, PT, CR, CT | PAPI-1, PAPI-2 [8] |
| 1211 | Male/5 years | Aplastic anemia | TI, TM, CA, CR, FE, AZ, AM, GE, TO, PO, CI, LO, NO, LE | CB, PI, CT | PT, IM, ME | PAPI-1, PAPI-2 [8] |
| 1212 | Female/14 years | Cavernous angioma | TI, PI, TM, PT, CA, CR, CT, FE, IM, ME, AZ, AM, GE, TO, PO, CI, LO, NO, LE | CB | PAPI-1, PAPI-2 [8] | |
| 1220 | Male/4 years | Osteosarcoma | AM, GE, TO, PO, NO, LE | CB, TI, PI, TM, CA, FE, AZ, CI, LO | PT, CR, CT, IM, ME | PAPI-1, PAPI-2, pKLC102 [5] |
| 1226 | Male/1 year | Biliary atresia | PO, CI, LO, NO, LE | TI | CB, PI, TM, PT, CA, CR, CT, FE, IM, ME, AZ, AM, GE, TO | PAPI-2 [11] |
| 1239 | Male/6 years | Acute myeloblastic leukemia | TI, FE, AZ, AM, GE, TO, PO, NO | CB, PI, TM, PT, CA, CI, LO, LE | CR, CT, IM, ME | PAPI-1, PAPI-2 [8] |
| 1241 | Female/7 years | Epoxy encephalopathy | PO | CB, TI, PI, TM, PT, CA, CR, CT, FE, IM, ME, AZ, AM, GE, TO, CI, LO, NO, LE | PAGI-1, PAPI-1, PAPI-2 [4] | |
S, Susceptible; I, Intermediate resistance; R, Resistant. CB, Carbenicillin; TI, Ticarcillin; PI, Piperacillin; TM, Ticarcillin/Clavulanic acid; PT, Piperacillin/Tazobactam; CA, Ceftazidime; CR, Ceftriaxone; CT, Cefotaxime; FE, Cefepime; IM, Imipenem; ME, Meropenem; AZ, Aztreonam; AM, Amikacin; GE, Gentamicin; TO, Tobramycin; PO, Polymyxin B; CI, Ciprofloxacin; LO, Lomefloxacin; NO, Norfloxacin; LE, Levofloxacin. GEIs, Genomic Islands; [number] correspond to GEIs genotype.